
Adult Immunization
Latest News

Rotavirus Vaccine Recommendation Change May Undo Decades of Progress

Semaglutide Reduces BMI by 13.5% in Children Aged 6-11 in Step Young Trial

FDA Approves Dexmedetomidine as First At-Home Treatment for Acute Agitation

Ascletis Submits FDA IND for ASC30_39 Oral Obesity Combination

Yoga-Based Cardiac Rehab Improves Quality of Life in Heart Failure Trial

Shorts










Latest Videos
Continuing Medical Education
All News

Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.

Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.

Survodutide Meets Cardiovascular Safety Endpoint in Phase 3 Obesity Trial
Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.

Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.

The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.

Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.

Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.

October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.

Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.


























































































